Furthermore, future research should aim to assess the applicability of PIV in different molecular subtypes of breast cancer, such as TNBC and HER2-positive disease, since tumor biology may significantly influence PIV levels and their prognostic significance. This evidence concerns the gene ERBB2 and breast carcinoma.